See more : Pine Care Group Limited (1989.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Devonian Health Group Inc. (DVHGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Devonian Health Group Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Processa Pharmaceuticals, Inc. (PCSA) Income Statement Analysis – Financial Results
- Canon Inc. (CAJ) Income Statement Analysis – Financial Results
- India Nippon Electricals Limited (INDNIPPON.BO) Income Statement Analysis – Financial Results
- Sally Beauty Holdings, Inc. (SBH) Income Statement Analysis – Financial Results
- GASE Energy, Inc. (GASE) Income Statement Analysis – Financial Results
Devonian Health Group Inc. (DVHGF)
About Devonian Health Group Inc.
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.82M | 2.35M | 2.31M | 1.47M | 2.14M | 5.94M | 3.20M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 11.83M | 1.45M | 1.74M | 1.72M | 2.21M | 2.82M | 2.95M | 276.55K | 0.00 | 0.00 |
| Gross Profit | 5.99M | 892.34K | 561.02K | -240.90K | -70.12K | 3.11M | 252.76K | -276.55K | 0.00 | 0.00 |
| Gross Profit Ratio | 33.62% | 38.05% | 24.34% | -16.34% | -3.27% | 52.44% | 7.90% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.29M | 1.43M | 778.54K | 610.25K | 1.54M | 884.38K | 1.12M | 426.51K | 536.99K | 116.97K |
| General & Administrative | 5.56M | 3.86M | 2.70M | 1.45M | 2.48M | 5.22M | 1.91M | 1.51M | 1.16M | 83.44K |
| Selling & Marketing | 0.00 | 0.00 | 117.64K | 0.00 | 0.00 | 196.43K | 68.07K | 0.00 | 0.00 | 0.00 |
| SG&A | 5.56M | 3.86M | 2.70M | 1.45M | 2.48M | 5.42M | 1.97M | 1.51M | 1.16M | 83.44K |
| Other Expenses | -858.44K | -4.32M | 0.00 | -107.88K | 221.65K | -14.38K | -3.29K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.99M | 892.34K | 3.47M | 2.02M | 4.01M | 6.30M | 3.09M | 1.94M | 1.70M | 89.01K |
| Cost & Expenses | 17.82M | 6.63M | 5.22M | 3.73M | 6.22M | 9.13M | 6.04M | 1.94M | 1.70M | 89.01K |
| Interest Income | 73.91K | 184.32K | 39.65K | 793.06K | 761.58K | 679.86K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 379.83K | 459.67K | 936.97K | 793.06K | 761.58K | 392.86K | 354.59K | 520.58K | 563.73K | 0.00 |
| Depreciation & Amortization | 672.83K | 423.45K | 863.87K | 1.03M | 1.04M | 1.02M | 640.71K | 276.55K | 275.89K | 208.91K |
| EBITDA | -171.98K | -3.72M | -2.01M | -1.23M | -2.81M | -2.18M | -2.29M | -1.72M | -1.45M | -1.68M |
| EBITDA Ratio | -0.97% | -158.46% | -87.15% | -83.39% | -131.33% | -36.73% | -68.75% | 0.00% | 0.00% | 0.00% |
| Operating Income | 0.00 | -4.28M | -2.87M | -2.26M | -4.60M | -3.75M | -3.20M | -2.51M | -2.29M | -89.01K |
| Operating Income Ratio | 0.00% | -182.63% | -124.63% | -153.26% | -214.76% | -63.11% | -99.86% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.22M | -316.18K | -575.39K | -1.04M | -289.65K | 450.78K | -88.53K | -1.62M | 45.53K | 5.29M |
| Income Before Tax | -1.22M | -4.60M | -3.45M | -3.35M | -4.37M | -3.22M | -3.28M | -4.13M | -2.24M | -89.01K |
| Income Before Tax Ratio | -6.87% | -196.11% | -149.59% | -226.92% | -204.13% | -54.27% | -102.62% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 936.97K | 793.06K | 983.23K | -243.16K | -96.81K | 241.81K | -420.00K | 570.60K |
| Net Income | -1.22M | -4.60M | -3.45M | -3.35M | -4.37M | -2.98M | -3.19M | -4.38M | -1.82M | -89.01K |
| Net Income Ratio | -6.87% | -196.11% | -149.59% | -226.92% | -204.13% | -50.18% | -99.60% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.03 | -0.03 | -0.04 | -0.06 | -0.04 | -0.05 | -0.13 | -0.07 | -0.05 |
| EPS Diluted | 0.00 | -0.03 | -0.03 | -0.04 | -0.06 | -0.04 | -0.05 | -0.13 | -0.07 | -0.05 |
| Weighted Avg Shares Out | 0.00 | 135.29M | 119.03M | 88.84M | 72.41M | 67.43M | 62.49M | 34.65M | 25.13M | 1.75M |
| Weighted Avg Shares Out (Dil) | 0.00 | 135.57M | 119.03M | 88.84M | 72.41M | 67.43M | 62.95M | 34.65M | 25.13M | 1.75M |
Devonian Health Group Reports First Quarter 2025 Financial Results and Grants Stock Options
Source: https://incomestatements.info
Category: Stock Reports